Reply: Posterior Cingulate Involvement Does Not Argue Against LATE--And Who Said It Does?
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - August 1, 2022 Category: Nuclear Medicine Authors: Rieger, A. C., Silverman, D. H. S. Tags: Letters Source Type: research

Posterior Cingulate Involvement Does Not Argue Against LATE
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - August 1, 2022 Category: Nuclear Medicine Authors: McCarter, S. J., Jones, D. T., Jack, C. R., Lowe, V., Botha, H. Tags: Letters Source Type: research

Total-Body PET Multiparametric Imaging of Cancer Using a Voxelwise Strategy of Compartmental Modeling
Conclusion: The time delay and appropriate kinetic model vary in different organs and lesions. Modeling of the time delay of the blood input function and model selection improved total-body multiparametric imaging. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - August 1, 2022 Category: Nuclear Medicine Authors: Wang, G., Nardo, L., Parikh, M., Abdelhafez, Y. G., Li, E., Spencer, B. A., Qi, J., Jones, T., Cherry, S. R., Badawi, R. D. Tags: Clinical Investigations Source Type: research

Efficient Delay Correction for Total-Body PET Kinetic Modeling Using Pulse Timing Methods
Conclusion: This study demonstrated the importance of delay correction in total-body PET. LE delay correction can be an efficient surrogate for JE, requiring a fraction of the computational time and allowing for rapid delay correction across more than 106 voxels in total-body PET datasets. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - August 1, 2022 Category: Nuclear Medicine Authors: Li, E. J., Spencer, B. A., Schmall, J. P., Abdelhafez, Y., Badawi, R. D., Wang, G., Cherry, S. R. Tags: Basic Science Investigations Source Type: research

Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of 89Zr-Labeled Anti-PD-L1 Antibody Formats
Conclusion: This study highlights the potential of designing radioligands with shorter pharmacokinetics for PD-L1 immuno-PET imaging in a preclinical model and encourages further clinical translation of such radioligands. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - August 1, 2022 Category: Nuclear Medicine Authors: Bouleau, A., Nozach, H., Dubois, S., Kereselidze, D., Chevaleyre, C., Wang, C.-I., Evans, M. J., Lebon, V., Maillere, B., Truillet, C. Tags: Basic Science Investigations Source Type: research

In Vivo Evaluation of 6 Analogs of 11C-ER176 as Candidate 18F-Labeled Radioligands for 18-kDa Translocator Protein
Conclusion: All 6 radioligands had good BPND and good time stability of VT. Among them, the o-fluoro, m-trifluoromethyl, and m-fluoro compounds were the 3 best candidates for development as radioligands with an 18F label. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - August 1, 2022 Category: Nuclear Medicine Authors: Lee, J.-H., Simeon, F. G., Liow, J.-S., Morse, C. L., Gladding, R. L., Santamaria, J. A. M., Henter, I. D., Zoghbi, S. S., Pike, V. W., Innis, R. B. Tags: Basic Science Investigations Source Type: research

SV2A PET Imaging Is a Noninvasive Marker for the Detection of Spinal Damage in Experimental Models of Spinal Cord Injury
Conclusion: 11C-UCB-J PET/CT imaging is a noninvasive marker for SV2A loss after SCI. Collectively, these findings indicate that SV2A PET may provide an objective measure of SCI and thus represent a valuable tool to evaluate novel therapeutics. Clinical assessment of SCI with SV2A PET imaging is highly recommended. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - August 1, 2022 Category: Nuclear Medicine Authors: Bertoglio, D., Halloin, N., Lombaerde, S. D., Jankovski, A., Verhaeghe, J., Nicaise, C., Staelens, S. Tags: Basic Science Investigations Source Type: research

Comparison of 11C-Pittsburgh Compound B and 18F-Flutemetamol White Matter Binding in PET
Conclusion: 11C-PiB and 18F-flutemetamol show a similar topographic pattern of uptake in white matter with a similar association with age in WMH and NAWM. 11C-PiB and 18F-flutemetamol can also effectively distinguish between WMH and NAWM. However, given its longer half-life, commercial availability, and higher binding potential, 18F-flutemetamol can be an alternative to 11C-PiB in molecular imaging studies specifically targeting multiple sclerosis to evaluate white matter integrity. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - August 1, 2022 Category: Nuclear Medicine Authors: Zeydan, B., Schwarz, C. G., Przybelski, S. A., Lesnick, T. G., Kremers, W. K., Senjem, M. L., Kantarci, O. H., Min, P. H., Kemp, B. J., Jack, C. R., Kantarci, K., Lowe, V. J. Tags: Clinical Investigations Source Type: research

Absolute Lymphocyte Count After COVID-19 Vaccination Is Associated with Vaccine-Induced Hypermetabolic Lymph Nodes on 18F-FDG PET/CT: A Focus in Breast Cancer Care
Conclusion: Patients with a normal ALC after COVID-19 vaccination were more likely to have v-HLNs on 18F-FDG PET/CT, both of which might be associated with a stronger immune response to vaccination. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - August 1, 2022 Category: Nuclear Medicine Authors: Seban, R.-D., Richard, C., Nascimento-Leite, C., Ghidaglia, J., Provost, C., Gonin, J., Tourneau, C. L., Romano, E., Deleval, N., Champion, L. Tags: Featured Article of the Month Source Type: research

Combination of Carriers with Complementary Intratumoral Microdistributions of Delivered {alpha}-Particles May Realize the Promise for 225Ac in Large, Solid Tumors
Conclusion: This strategy demonstrates that more uniform microdistributions of the delivered α-particles within established solid tumors improve efficacy even at lower tumor doses. Augmentation of antibody-targeted α-particle therapies with tumor-responsive liposomes may address partial tumor irradiation, improving therapeutic effects. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - August 1, 2022 Category: Nuclear Medicine Authors: Howe, A., Bhatavdekar, O., Salerno, D., Josefsson, A., Pacheco-Torres, J., Bhujwalla, Z. M., Gabrielson, K. L., Sgouros, G., Sofou, S. Tags: Featured Basic Science Article Source Type: research

Long-Term Outcomes of Transarterial Radioembolization for Large Single Hepatocellular Carcinoma: A Comparison to Resection
Conclusion: Compared with surgical resection for large single nodular HCC, TARE showed a comparable OS, TTP, and TTIP and a better safety profile. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - August 1, 2022 Category: Nuclear Medicine Authors: Kim, J., Kim, J. Y., Lee, J.-H., Sinn, D. H., Hur, M. H., Hong, J. H., Park, M. K., Cho, H. J., Choi, N. R., Lee, Y. B., Cho, E. J., Yu, S. J., Kim, Y. J., Paeng, J. C., Kim, H. C., Yi, N.-J., Lee, K.-W., Suh, K.-S., Hyun, D., Kim, J. M., Yoon, J.-H. Tags: Clinical Investigations Source Type: research

18F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Curative-Intent Radiation Therapy: A Bicentric Retrospective Study
Conclusion: 18F-rhPSMA-7 PET/CT demonstrates high detection rates in prostate cancer patients with BCR after primary radiation therapy, even at low PSA values. Its diagnostic efficacy is comparable to published data for other PSMA ligands. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - August 1, 2022 Category: Nuclear Medicine Authors: Ilhan, H., Kroenke, M., Wurzer, A., Unterrainer, M., Heck, M., Belka, C., Knorr, K., Langbein, T., Rauscher, I., Schmidt-Hegemann, N.-S., Schiller, K., Bartenstein, P., Wester, H.-J., Eiber, M. Tags: Clinical Investigations Source Type: research

Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry
Conclusion: Both 177Lu-PSMA I&T and 177Lu-PSMA-617 PRLT demonstrated favorable safety in mCRPC patients. The highest absorbed doses among healthy organs were in the lacrimal and parotid glands—not, however, resulting in any significant clinical sequel. 177Lu-PSMA-617 demonstrated a higher absorbed dose to the whole-body and lacrimal glands but a lower renal dose than did 177Lu-PSMA I&T. The mean absorbed tumor doses were comparable for both 177Lu-PSMA I&T and 177Lu-PSMA-617. There was a large interpatient variability in the dosimetry parameters. Therefore, individual patient-based dosimetry seems favorabl...
Source: Journal of Nuclear Medicine - August 1, 2022 Category: Nuclear Medicine Authors: Schuchardt, C., Zhang, J., Kulkarni, H. R., Chen, X., Muller, D., Baum, R. P. Tags: Clinical Investigations Source Type: research

68Ga-PSMA PET/CT for Response Assessment and Outcome Prediction in Metastatic Prostate Cancer Patients Treated with Taxane-Based Chemotherapy
Conclusion: This retrospective analysis suggests that 68Ga-PSMA-11 PET/CT is a promising imaging modality for assessing response to taxane-based chemotherapy in metastatic PCa. Changes in PSMA expression might be used as a predictive biomarker for OS to help tailor individual therapy and select eligible patients for clinical trials. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - August 1, 2022 Category: Nuclear Medicine Authors: Shagera, Q. A., Artigas, C., Karfis, I., Critchi, G., Chanza, N. M., Sideris, S., Peltier, A., Paesmans, M., Gil, T., Flamen, P. Tags: Clinical Investigations Source Type: research

Predictors of 18F-DCFPyL PET/CT Positivity in Patients with Biochemical Recurrence of Prostate Cancer After Local Therapy
Conclusion: 18F-DCFPyL PET/CT offers high detection rates in BCR PCa patients. PSA and PSAdt are able to predict scan positivity and disease location. Furthermore, the presence of bone or visceral lesions is associated with shorter intervals from treatment than are prostate-bed–only recurrences. These tools might guide clinicians to select the most suitable candidates for 18F-DCFPyL PET/CT imaging. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - August 1, 2022 Category: Nuclear Medicine Authors: Mena, E., Rowe, S. P., Shih, J. H., Lindenberg, L., Turkbey, B., Fourquet, A., Lin, F. I., Adler, S., Eclarinal, P., McKinney, Y. L., Citrin, D. E., Dahut, W., Wood, B. J., Chang, R., Levy, E., Merino, M., Gorin, M. A., Pomper, M. G., Pinto, P. A., Eary, Tags: Clinical Investigations Source Type: research